John Lepore's next move post-GSK announced

After 17 years at GSK (LSE: GSK), John Lepore’s departure from the UK pharma major was announced last week.

He left his role as senior vice president and head of research at GSK at a time when the London-based drugmaker is re-shuffling its R&D teams to create a distinct focus around each of its core therapy area.

"The identification of a whole new world of previously unknown proteins has enabled the exciting opportunity for ProFound to develop many new classes of drug targets"Dr Lepore’s next stop is the Boston-based life sciences venture capital firm Flagship Pioneering and its portfolio company ProFound Therapeutics, a biotech that claims to be pioneering the discovery of an expanded human proteome and using its newfound insights to unlock potential new medicines.